Fundraising FoxT3D Therapeutics
Research Triangle Park, US · Founded 2013 · Delaware corporation
Find your way into T3D Therapeutics
Sign up to see every warm intro you have to T3D Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the T3D Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Founders & leadership
T3D Therapeutics was founded in 2013 by John Didsbury.
JD
John DidsburyFounderHe has held executive leadership roles spanning strategy, operations, and drug discovery at GSK, Nuada Pharmaceuticals, DARA BioSciences, and the Drug Discovery Center of Innovation.
Board
TM
Tom MendellBoard director
CL
Charles LineberryBoard director
JA
John A. GoldenBoard director
BB
Barry BuzoganyBoard director
Reported raises · per SEC filings
Form D private placements$29.6M disclosed across 6 rounds · 2014–2022
▶$6MraisedSep 2022 · 23 investors · PharmaceuticalsRule 506(b)
▶$6MraisedSep 2022 · 23 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Donald ParkerDirector
- John DidsburyExecutive Officer, Director, Promoter
- Tom MendellDirector
- Charles LineberryDirector
- Barry BuzoganyDirector
- John GoldenDirector
- David KeimDirector
- Offering amount
- $7.5M
- Amount sold
- $6M
- First sale
- Aug 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$15MraisedNov 2019 · 1 investors · PharmaceuticalsRule 506(b)
▶$15MraisedNov 2019 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Tom MendellDirector
- Barry BuzoganyDirector
- Charles LineberryDirector
- John DidsburyExecutive Officer, Director, Promoter
- John A. GoldenDirector
- Offering amount
- $15M
- Amount sold
- $15M
- First sale
- Oct 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$6MraisedMar 2018 · 1 investors · PharmaceuticalsRule 506(b)
▶$6MraisedMar 2018 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Charles LineberryDirector
- John DidsburyExecutive Officer, Director, Promoter
- Barry BuzoganyDirector
- John A. GoldenDirector
- Tom MendellDirector
- Offering amount
- $18M
- Amount sold
- $6M
- First sale
- Mar 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$711.3KraisedJan 2018 · 30 investors · PharmaceuticalsRule 506(b)
▶$711.3KraisedJan 2018 · 30 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Tom MendellDirector
- Charles LineberryDirector
- John A. GoldenDirector
- John DidsburyExecutive Officer, Director, Promoter
- Barry BuzoganyDirector
- Offering amount
- $1M
- Amount sold
- $711.3K
- First sale
- Jan 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.2MraisedMar 2016 · 18 investors · PharmaceuticalsRule 506(b)
▶$1.2MraisedMar 2016 · 18 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- John DidsburyExecutive Officer, Director, Promoter
- Charles LineberryDirector
- Barry BuzoganyDirector
- John A. GoldenDirector
- Offering amount
- $3.8M
- Amount sold
- $1.2M
- Minimum investment
- $100K
- Sales commissions
- $152.4K
- Finders' fees
- $15K
- Proceeds to insiders
- $210K
- Placement agents
- ROI Capital Partners, LLC
- First sale
- Feb 2015
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 06b
▶$661KraisedMar 2014 · 9 investors · PharmaceuticalsRule 506(b)
▶$661KraisedMar 2014 · 9 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Charles LineberryDirector
- John DidsburyExecutive Officer, Director
- Barry BuzoganyDirector
- Offering amount
- $2.5M
- Amount sold
- $661K
- Minimum investment
- $25K
- Proceeds to insiders
- $150K
- First sale
- Mar 2014
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- Who founded T3D Therapeutics?
- T3D Therapeutics was founded by John Didsbury in 2013.
- How much funding has T3D Therapeutics raised?
- T3D Therapeutics has disclosed $29.6M raised across 6 rounds.
- Where is T3D Therapeutics headquartered?
- T3D Therapeutics is headquartered in Research Triangle Park, US.